PMID- 24569640
OWN - NLM
STAT- MEDLINE
DCOM- 20140512
LR  - 20240321
IS  - 1476-6256 (Electronic)
IS  - 0002-9262 (Print)
IS  - 0002-9262 (Linking)
VI  - 179
IP  - 7
DP  - 2014 Apr 1
TI  - Rheumatoid arthritis in the Women's Health Initiative: methods and baseline 
      evaluation.
PG  - 917-26
LID - 10.1093/aje/kwu003 [doi]
AB  - Second-generation assays for anti-cyclic citrullinated peptide (anti-CCP), a 
      highly sensitive and specific marker for rheumatoid arthritis (RA), have 
      redefined the epidemiology of RA. In the Women's Health Initiative (WHI) RA study 
      (2009-2011), we evaluated the prevalence of anti-CCP positivity among 15,691 
      (10.2% of 161,808) WHI participants aged 50-79 years who reported RA. Using 
      stored baseline specimens, we measured serum anti-CCP, rheumatoid factor (RF), 
      and antinuclear antibody in a defined sample of 9,988 of black, white, and 
      Hispanic women. In a subset of women, we measured plasma cytokine levels and 
      number of copies of the human leukocyte antigen (HLA)-DRB1 (HLA-DRB1) shared 
      epitope in DNA by means of Luminex polymerase chain reaction typing (Luminex 
      Corporation, Austin, Texas). We validated classification of probable clinical RA 
      in 2 clinics as anti-CCP positivity or self-reported validated use of 
      disease-modifying antirheumatic drugs (DMARDs). The prevalence of anti-CCP 
      positivity was 8.1%, and the prevalence of RF positivity was approximately 16.0%. 
      DMARD use including prednisone was reported by 1,140 (11.4%) participants (841 
      excluding prednisone) but by 57.5% of anti-CCP-positive women. The prevalence of 
      2 shared epitopes was also much higher for anti-CCP-positive women (18.2%, as 
      opposed to only 5.5% for women with anti-CCP-negative DMARD-positive RA and 6.6% 
      for anti-CCP-negative, RF-negative DMARD nonusers). Median cytokine levels were 
      much higher for anti-CCP-positive/RF-positive women. Women with anti-CCP-positive 
      RA and anti-CCP-negative RA had different characteristics with regard to HLA 
      shared epitope, cigarette smoking, and inflammation (cytokines).
FAU - Kuller, Lewis H
AU  - Kuller LH
FAU - Mackey, Rachel H
AU  - Mackey RH
FAU - Walitt, Brian T
AU  - Walitt BT
FAU - Deane, Kevin D
AU  - Deane KD
FAU - Holers, V Michael
AU  - Holers VM
FAU - Robinson, William H
AU  - Robinson WH
FAU - Sokolove, Jeremy
AU  - Sokolove J
FAU - Chang, Yuefang
AU  - Chang Y
FAU - Moreland, Larry W
AU  - Moreland LW
LA  - eng
GR  - N01WH42129/WH/WHI NIH HHS/United States
GR  - N01WH44221/WH/WHI NIH HHS/United States
GR  - N01WH42132/WH/WHI NIH HHS/United States
GR  - N01WH24152/WH/WHI NIH HHS/United States
GR  - N01WH32111-N01WH32113/WH/WHI NIH HHS/United States
GR  - N01WH42107/HL/NHLBI NIH HHS/United States
GR  - N01WH32115/WH/WHI NIH HHS/United States
GR  - N01WH32106/WH/WHI NIH HHS/United States
GR  - N01WH32113/WH/WHI NIH HHS/United States
GR  - N01WH32119/WH/WHI NIH HHS/United States
GR  - N01WH32108/WH/WHI NIH HHS/United States
GR  - N01WH32111/WH/WHI NIH HHS/United States
GR  - N01WH32100/WH/WHI NIH HHS/United States
GR  - N01 WH32115/WH/WHI NIH HHS/United States
GR  - N01WH32109/WH/WHI NIH HHS/United States
GR  - N01WH32122/WH/WHI NIH HHS/United States
GR  - R56 AI103023/AI/NIAID NIH HHS/United States
GR  - U19 AI050864/AI/NIAID NIH HHS/United States
GR  - N01WH42129-N01WH42132/WH/WHI NIH HHS/United States
GR  - N01WH32100-N01WH32102/WH/WHI NIH HHS/United States
GR  - N01WH32118/HL/NHLBI NIH HHS/United States
GR  - N01WH42107-N01WH42126/WH/WHI NIH HHS/United States
GR  - N01WH32102/HL/NHLBI NIH HHS/United States
GR  - N01WH42126/HL/NHLBI NIH HHS/United States
GR  - N01WH22110/WH/WHI NIH HHS/United States
GR  - N01WH32105/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20140224
PL  - United States
TA  - Am J Epidemiol
JT  - American journal of epidemiology
JID - 7910653
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Immunologic Factors)
RN  - 0 (Peptides, Cyclic)
RN  - 0 (cyclic citrullinated peptide)
RN  - 9009-79-4 (Rheumatoid Factor)
SB  - IM
MH  - Aged
MH  - Antibodies, Antinuclear/blood
MH  - Antirheumatic Agents/*administration & dosage
MH  - Arthritis, Rheumatoid/*blood/epidemiology/genetics
MH  - Biomarkers/blood
MH  - Cytokines/blood
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - HLA-DRB1 Chains/blood
MH  - Humans
MH  - Immunologic Factors/blood
MH  - Middle Aged
MH  - Peptides, Cyclic/*blood/immunology
MH  - Polymerase Chain Reaction
MH  - Rheumatoid Factor/*blood
MH  - Seroepidemiologic Studies
MH  - United States/epidemiology
MH  - Women's Health/*statistics & numerical data
PMC - PMC3969537
OTO - NOTNLM
OT  - cytokines
OT  - epidemiologic methods
OT  - genetics
OT  - rheumatoid arthritis
EDAT- 2014/02/27 06:00
MHDA- 2014/05/13 06:00
PMCR- 2015/04/01
CRDT- 2014/02/27 06:00
PHST- 2014/02/27 06:00 [entrez]
PHST- 2014/02/27 06:00 [pubmed]
PHST- 2014/05/13 06:00 [medline]
PHST- 2015/04/01 00:00 [pmc-release]
AID - kwu003 [pii]
AID - 10.1093/aje/kwu003 [doi]
PST - ppublish
SO  - Am J Epidemiol. 2014 Apr 1;179(7):917-26. doi: 10.1093/aje/kwu003. Epub 2014 Feb 
      24.